Sentinel node mapping in high-intermediate and high-risk endometrial cancer : Analysis of 5-year oncologic outcomes
© 2024 Published by Elsevier Ltd..
OBJECTIVE: To assess 5-year oncologic outcomes of apparent early-stage high-intermediate and high-risk endometrial cancer undergoing sentinel node mapping versus systematic lymphadenectomy.
METHODS: This is a multi-institutional retrospective, propensity-matched study evaluating data of high-intermediate and high-risk endometrial cancer (according to ESGO/ESTRO/ESP guidelines) undergoing sentinel node mapping versus systematic pelvic lymphadenectomy (with and without para-aortic lymphadenectomy). Survival outcomes were assessed using Kaplan-Meier and Cox proportional hazard methods.
RESULTS: Overall, the charts of 242 patients with high-intermediate and high-risk endometrial cancer were retrieved. Data on 73 (30.1%) patients undergoing hysterectomy plus sentinel node mapping were analyzed. Forty-two (57.5%) and 31 (42.5%) patients were classified in the high-intermediate and high-risk groups, respectively. Unilateral sentinel node mapping was achieved in all patients. Bilateral mapping was achieved in 67 (91.7%) patients. Three (4.1%) patients had site-specific lymphadenectomy (two pelvic areas only and one pelvic plus para-aortic area), while adjunctive nodal dissection was omitted in the hemipelvis of the other three (4.1%) patients. Sentinel nodes were detected in the para-aortic area in eight (10.9%) patients. Twenty-four (32.8%) patients were diagnosed with nodal disease. A propensity-score matching was used to compare the aforementioned group of patients undergoing sentinel node mapping with a group of patients undergoing lymphadenectomy. Seventy patient pairs were selected (70 having sentinel node mapping vs. 70 having lymphadenectomy). Patients undergoing sentinel node mapping experienced similar 5-year disease-free survival (HR: 1.233; 95%CI: 0.6217 to 2.444; p = 0.547, log-rank test) and 5-year overall survival (HR: 1.505; 95%CI: 0.6752 to 3.355; p = 0.256, log-rank test) than patients undergoing lymphadenectomy.
CONCLUSIONS: Sentinel node mapping does not negatively impact 5-year outcomes of high-intermediate and high-risk endometrial cancer. Further prospective studies are warranted.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:50 |
|---|---|
| Enthalten in: |
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology - 50(2024), 4 vom: 26. Apr., Seite 108018 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
Endometrial cancer |
|---|
| Anmerkungen: |
Date Completed 01.04.2024 Date Revised 01.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ejso.2024.108018 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369179870 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369179870 | ||
| 003 | DE-627 | ||
| 005 | 20240401232708.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240302s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejso.2024.108018 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1359.xml |
| 035 | |a (DE-627)NLM369179870 | ||
| 035 | |a (NLM)38428106 | ||
| 035 | |a (PII)S0748-7983(24)00070-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cuccu, Ilaria |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Sentinel node mapping in high-intermediate and high-risk endometrial cancer |b Analysis of 5-year oncologic outcomes |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.04.2024 | ||
| 500 | |a Date Revised 01.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024 Published by Elsevier Ltd. | ||
| 520 | |a OBJECTIVE: To assess 5-year oncologic outcomes of apparent early-stage high-intermediate and high-risk endometrial cancer undergoing sentinel node mapping versus systematic lymphadenectomy | ||
| 520 | |a METHODS: This is a multi-institutional retrospective, propensity-matched study evaluating data of high-intermediate and high-risk endometrial cancer (according to ESGO/ESTRO/ESP guidelines) undergoing sentinel node mapping versus systematic pelvic lymphadenectomy (with and without para-aortic lymphadenectomy). Survival outcomes were assessed using Kaplan-Meier and Cox proportional hazard methods | ||
| 520 | |a RESULTS: Overall, the charts of 242 patients with high-intermediate and high-risk endometrial cancer were retrieved. Data on 73 (30.1%) patients undergoing hysterectomy plus sentinel node mapping were analyzed. Forty-two (57.5%) and 31 (42.5%) patients were classified in the high-intermediate and high-risk groups, respectively. Unilateral sentinel node mapping was achieved in all patients. Bilateral mapping was achieved in 67 (91.7%) patients. Three (4.1%) patients had site-specific lymphadenectomy (two pelvic areas only and one pelvic plus para-aortic area), while adjunctive nodal dissection was omitted in the hemipelvis of the other three (4.1%) patients. Sentinel nodes were detected in the para-aortic area in eight (10.9%) patients. Twenty-four (32.8%) patients were diagnosed with nodal disease. A propensity-score matching was used to compare the aforementioned group of patients undergoing sentinel node mapping with a group of patients undergoing lymphadenectomy. Seventy patient pairs were selected (70 having sentinel node mapping vs. 70 having lymphadenectomy). Patients undergoing sentinel node mapping experienced similar 5-year disease-free survival (HR: 1.233; 95%CI: 0.6217 to 2.444; p = 0.547, log-rank test) and 5-year overall survival (HR: 1.505; 95%CI: 0.6752 to 3.355; p = 0.256, log-rank test) than patients undergoing lymphadenectomy | ||
| 520 | |a CONCLUSIONS: Sentinel node mapping does not negatively impact 5-year outcomes of high-intermediate and high-risk endometrial cancer. Further prospective studies are warranted | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Endometrial cancer | |
| 650 | 4 | |a High-risk | |
| 650 | 4 | |a Intermediate-high risk | |
| 650 | 4 | |a Sentinel node mapping | |
| 700 | 1 | |a Raspagliesi, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Malzoni, Mario |e verfasserin |4 aut | |
| 700 | 1 | |a Vizza, Enrico |e verfasserin |4 aut | |
| 700 | 1 | |a Papadia, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Di Donato, Violante |e verfasserin |4 aut | |
| 700 | 1 | |a Giannini, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a De Iaco, Pierandrea |e verfasserin |4 aut | |
| 700 | 1 | |a Perrone, Anna Myriam |e verfasserin |4 aut | |
| 700 | 1 | |a Plotti, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Angioli, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Casarin, Jvan |e verfasserin |4 aut | |
| 700 | 1 | |a Ghezzi, Fabio |e verfasserin |4 aut | |
| 700 | 1 | |a Cianci, Stefano |e verfasserin |4 aut | |
| 700 | 1 | |a Vizzielli, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Restaino, Stefano |e verfasserin |4 aut | |
| 700 | 1 | |a Petrillo, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Sorbi, Flavia |e verfasserin |4 aut | |
| 700 | 1 | |a Multinu, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Schivardi, Gabriella |e verfasserin |4 aut | |
| 700 | 1 | |a De Vitis, Luigi Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Falcone, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Lalli, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Berretta, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Mueller, Michael D |e verfasserin |4 aut | |
| 700 | 1 | |a Tozzi, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Chiantera, Vito |e verfasserin |4 aut | |
| 700 | 1 | |a Benedetti Panici, Pierluigi |e verfasserin |4 aut | |
| 700 | 1 | |a Fanfani, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Scambia, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Bogani, Giorgio |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology |d 1993 |g 50(2024), 4 vom: 26. Apr., Seite 108018 |w (DE-627)NLM01262862X |x 1532-2157 |7 nnns |
| 773 | 1 | 8 | |g volume:50 |g year:2024 |g number:4 |g day:26 |g month:04 |g pages:108018 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ejso.2024.108018 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 50 |j 2024 |e 4 |b 26 |c 04 |h 108018 | ||